Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

Home Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
nab-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program
Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety

Comments

Comments are closed.